Syma Iqbal, MD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3907
vCardDownload vCard
    Other Positions
    Title(s)Medical Director, Inpatient Services, Norris Cancer Hospital

    Title(s)Medical Director for Ambulatory Services/Infusion Center

    Title(s)Associate Cancer Physician in Chief


    Collapse Overview 
    Collapse Overview
    Dr. Syma Iqbal graduated from the Keck School of Medicine of USC in 1995 and completed a Hematology and Oncology Fellowship in 2001. She is currently an Associate Professor in the Division of Oncology at the Keck School of Medicine/Norris Comprehensive Cancer Center and Section Chief of Gastrointestinal Oncology. She is the Associate Cancer Physician in Chief for USC Norris Comprehensive Cancer Center and Keck Medicine of USC and serves as Medical Director of both Ambulatory/Infusion and Inpatient Services for Norris Cancer Hospital. Currently, Dr. Iqbal Chairs the Norris Clinical Investigations Committee. Dr. Iqbal is also an accomplished clinical researcher and has led and participated in trials for gastrointestinal malignancies. She is a national thought leader in the systemic therapy of esophageal and gastric cancer, and her national leadership posts include serving as co-Chair of the Southwest Oncology Group Esophago-Gastric Committee and Chair of the National Cancer Institute’s Esophago-Gastric Task Force.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int J Cancer. 2024 May 15; 154(10):1794-1801. Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz HJ, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, El Khoueiry A, Azad NS. PMID: 38312102.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023; 15:265-275. Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. PMID: 36969544; PMCID: PMC10032141.
      View in: PubMed   Mentions:
    3. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clin Cancer Res. 2020 11 15; 26(22):5943-5951. Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Tokunaga R, Naseem M, Barzi A, Iqbal S, Zhang W, Soni S, Hwang JJ, Philip PA, Sciallero S, Korn WM, Marshall JL, Lenz HJ. PMID: 32883742; PMCID: PMC8970533.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    4. Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist. 2020 12; 25(12):e1879-e1885. Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei DR, Cologne KG, Lenz HJ. PMID: 32649004; PMCID: PMC8186403.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    5. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. J Clin Oncol. 2020 02 10; 38(5):472-479. Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. PMID: 31815582; PMCID: PMC7007287.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    6. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. PMID: 28223062; PMCID: PMC5809128.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansCTClinical Trials
    7. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015 Jul 01; 121(13):2193-7. Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD. PMID: 25827820; PMCID: PMC4589423.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    8. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ. PMID: 25203738; PMCID: PMC4218879.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    9. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014 Oct 01; 120(19):2980-5. Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD. PMID: 25041791; PMCID: PMC4284963.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    10. New directions in perioperative management of locally advanced esophagogastric cancer. Am Soc Clin Oncol Educ Book. 2014; e172-8. Burtness B, Ilson D, Iqbal S. PMID: 24857100.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM. PMID: 23712328; PMCID: PMC3779138.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    12. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. PMID: 23568716; PMCID: PMC3775976.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    13. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 01; 29(34):4555-60. Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. PMID: 22025151; PMCID: PMC3236655.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    14. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. Ann Surg Oncol. 2012 Feb; 19(2):478-85. Cohen DJ, Newman E, Iqbal S, Chang RY, Potmesil M, Ryan T, Donahue B, Chandra A, Liu M, Utate M, Hiotis S, Pachter LH, Hochster H, Muggia F. PMID: 21769462.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. PMID: 21556747; PMCID: PMC3519425.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    16. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. PMID: 20142723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    17. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics. 2011 Jan; 12(1):27-39. Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ. PMID: 21174620; PMCID: PMC3836679.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    18. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010 Sep; 5(9):1472-6. Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, Blanke CD. PMID: 20631636; PMCID: PMC2928397.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    19. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. PMID: 20062993.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    20. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. PMID: 19169683.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    21. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008 Apr 15; 68(8):3037-42. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18413774.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    22. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    23. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007 Dec; 8(12):1705-13. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ. PMID: 18086000.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    24. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007 Aug 20; 25(24):3726-31. Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, El-Khoueiry A, Iqbal S, Sherrod AE, Lurje G, Lenz HJ. PMID: 17704422.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    25. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20; 25(24):3712-8. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. PMID: 17704420.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansCTClinical Trials
    26. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2007 Jan; 1(1):23-30. Rhodes KE, Zhang W, Yang D, Press OA, Gordon M, Vallböhmer D, Schultheis AM, Lurje G, Ladner RD, Fazzone W, Iqbal S, Lenz HJ. PMID: 19356014.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    27. Molecular determinants of irinotecan efficacy. Int J Cancer. 2006 Nov 15; 119(10):2435-42. Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD, Lenz HJ. PMID: 16894565.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    28. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. PMID: 17241515.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    29. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ. PMID: 17026791.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    30. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. PMID: 16847424.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    31. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics. 2006 Jul; 16(7):475-83. Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. PMID: 16788380.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    32. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. PMID: 16379039.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    33. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan; 7(1):67-88. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. PMID: 16354126.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    34. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005 Oct; 23(5):485-7. Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, Abbruzzese JL. PMID: 16133800.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    35. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005 May 20; 23(15):3536-44. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. PMID: 15908664.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    36. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. PMID: 15809878.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    37. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 17):10-6. Iqbal S, Lenz HJ. PMID: 15696025.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    38. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Rev Anticancer Ther. 2004 Dec; 4(6):947-55. Iqbal S, Lenz HJ. PMID: 15606325.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S32-9. Iqbal S, Lenz HJ. PMID: 15309512.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    40. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics. 2004 May; 14(5):319-27. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD. PMID: 15115918.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCells
    41. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest. 2004; 22(5):762-73. Iqbal S, Stoehlmacher J, Lenz HJ. PMID: 15581057.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. Molecular predictors of treatment and outcome in colorectal cancer. Curr Gastroenterol Rep. 2003 Oct; 5(5):399-405. Iqbal S, Lenz HJ. PMID: 12959721.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Targeted therapy and pharmacogenomic programs. Cancer. 2003 Apr 15; 97(8 Suppl):2076-82. Iqbal S, Lenz HJ. PMID: 12673699.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Syma's Networks
    Concepts (193)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.